Chromadex Corp reports results for the quarter ended in June - Earnings Summary

Niagen Bioscience

07/08/2024 23:13

* Chromadex Corp  CDXC.OQ  reported quarterly breakeven
results​​
per share for the quarter ended in June, higher than the same
quarter last year, when the company reported EPS of -3 cents. 
The mean expectation of three analysts for the quarter was for a
loss of 2 cents per share. Wall Street expected results to range
from -3 cents to -1 cents per share.
    * Revenue rose 11.9% to $22.74 million from a year ago;
analysts
expected $23.44 million. 
    * Chromadex Corp's reported EPS for the quarter was
breakeven
results​.
    * The company reported a quarterly loss of $15 thousand.
    * Chromadex Corp shares had risen by 3.3% this quarter and
gained 97.2% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had fallen by
about 50%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Chromadex Corp is
$6.70 
This summary was machine generated from LSEG data August 7 at
10:12 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2024      -0.02          0.00           Beat
 Mar. 31 2024      -0.02          -0.01          Beat
 Dec. 31 2023      -0.03          0.00           Beat
 Sep. 30 2023      -0.03          -0.01          Beat